Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDNF | P23560 | 3/20 | 0.53 |
| ▸ | MDK | P21741 | 3/20 | 0.53 |
| ▸ | PTN | P21246 | 2/20 | 0.53 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | FGF2 | P09038 | 7/20 | 0.42 |
| ▸ | HPSE | Q9Y251 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13321923 | 0.87 | BDNF (0.54) | BDNFMDKPTNF10FGF2 | |
| SCHEMBL13431463 | 0.87 | MDK (0.56) | BDNFMDKPTNF10FGF2 | |
| SCHEMBL13596935 | 0.85 | MDK (0.58) | BDNFMDKPTNF10FGF2 | |
| SCHEMBL13431447 | 0.85 | MDK (0.58) | BDNFMDKPTNF10FGF2 | |
| SCHEMBL17885071 | 0.85 | F10 (0.57) | BDNFMDKPTNF10FGF2 | |
| SCHEMBL13596920 | 0.84 | MDK (0.54) | BDNFMDKPTNF10FGF2 | |
| SCHEMBL13321927 | 0.83 | MDK (0.51) | BDNFMDKPTNF10FGF2 | |
| SCHEMBL13596899 | 0.81 | MDK (0.50) | BDNFMDKPTNF10FGF2 | |
| SCHEMBL15481379 | 0.80 | F10 (0.56) | BDNFMDKPTNF10FGF2 | |
| SCHEMBL15481373 | 0.80 | F10 (0.56) | BDNFMDKPTNF10FGF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219161-A1 | Preparation Process Of Oligoglycosaminoglycan, And Reducing End Glucuronic Acid Type Oligochondroitin Sulfate And Pharmaceutical Composition Comprising The Same | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219161-A1 | Preparation Process Of Oligoglycosaminoglycan, And Reducing End Glucuronic Acid Type Oligochondroitin Sulfate And Pharmaceutical Composition Comprising The Same | OSTC, B3GAT3, CSGALNACT1 | BDNF 4038/4885MDK 3375/4885PTN 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.